<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>IgG subclasses: Physical properties, genetics, and biologic functions</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">IgG subclasses: Physical properties, genetics, and biologic functions</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">IgG subclasses: Physical properties, genetics, and biologic functions</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan P Knutsen, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jordan S Orange, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anna M Feldweg, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 01, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>This topic will review the structure, normal serum concentrations, genetics, and biologic properties of immunoglobulin G (IgG) subclasses. Disorders associated with increased or decreased levels of IgG subclasses are mentioned briefly. IgG subclass deficiency is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/3906.html" rel="external">"IgG subclass deficiency"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PROPERTIES OF IgG SUBCLASSES</span><span class="headingEndMark"> — </span>IgG is composed of four subclasses: IgG1, IgG2, IgG3, and IgG4 [<a href="#rid1">1-9</a>]. The structure, genetics, and function of the IgG subclasses are reviewed in this section. Detailed discussions of these topics as they apply to immunoglobulins in general are presented separately. (See  <a class="medical medical_review" href="/d/html/3971.html" rel="external">"Structure of immunoglobulins"</a> and  <a class="medical medical_review" href="/d/html/3977.html" rel="external">"Immunoglobulin genetics"</a>.)</p><p class="headingAnchor" id="H22335778"><span class="h2">Structures and physical properties</span><span class="headingEndMark"> — </span>The four IgG subclasses are present in the serum in monomeric form. The tertiary structures of the IgG subclasses are similar, although they differ in the location and number of interchain-disulfide bonds  (<a class="graphic graphic_figure graphicRef110439" href="/d/graphic/110439.html" rel="external">figure 1</a>). All four IgG subclasses cross the placenta  (<a class="graphic graphic_table graphicRef110543" href="/d/graphic/110543.html" rel="external">table 1</a>) [<a href="#rid10">10-12</a>].</p><p>The determination of immunoglobulin class and/or subclass is based on differences in the heavy chain constant (CH) regions  (<a class="graphic graphic_figure graphicRef110439" href="/d/graphic/110439.html" rel="external">figure 1</a>). Functional differences among the subclasses arise from structural variation in both the Fc regions and in the hinge regions (the area where the variable or Fab regions are joined to the Fc region) [<a href="#rid1">1</a>].</p><p>The Fc region of each IgG subclass has a distinct affinity for phagocyte membrane Fc-gamma-receptors (FcγR)  (<a class="graphic graphic_table graphicRef110543" href="/d/graphic/110543.html" rel="external">table 1</a>). The binding of IgG molecules to FcγRs is important for initiating phagocytosis. IgG1 and IgG3 bind FcγRI, FcγRII, and FcγRIII; IgG2 binds FcγRII; and IgG4 binds FcγRI and FcγRII [<a href="#rid10">10-13</a>]. (See <a class="local">'Biologic functions'</a> below.)</p><p>An IgG molecule is composed of two identical heavy (H) chains and two identical light (L) chains, which usually results in two identical antigen-binding sites on the Fab arms. However, IgG4 antibodies have unique structural and functional properties and undergo "half antibody exchange," resulting in recombined antibodies composed of two different binding specificities [<a href="#rid14">14</a>]. A large fraction of IgG4 molecules exchange H-L dimer partners, resulting in a hybrid antibody that contains two different Fab arms with different antigen specificities. Although this antibody can only bind monovalently, it is capable of cross-linking two different antigens [<a href="#rid15">15</a>]. The functional significance of this characteristic is discussed below. (See <a class="local">'Opsonization'</a> below.)</p><p>The hinge regions of antibody molecules allow for rotation and flexion of the Fab arms. The degree of flexibility depends on the amount of inter-heavy chain disulfide bonds present within the hinge [<a href="#rid5">5</a>]. In decreasing order, the relative flexibility of the hinge regions of the IgG subclasses is as follows: IgG3&gt;IgG1&gt;IgG4&gt;IgG2 [<a href="#rid16">16</a>]. In addition, the number of amino acids in the hinge region differs among the subclasses: IgG3 has 62 amino acid residues, IgG1 has 15 amino acid residues, and IgG2 and IgG4 have 12 amino acid residues [<a href="#rid17">17</a>]. This increased flexibility may also account for the increased complement activation and FcR binding affinity. (See <a class="local">'Biologic functions'</a> below.)</p><p class="headingAnchor" id="H3396734"><span class="h2">Normal serum concentrations</span><span class="headingEndMark"> — </span>The IgG subclasses are named according to their abundance in the serum  (<a class="graphic graphic_table graphicRef110543" href="/d/graphic/110543.html" rel="external">table 1</a>) [<a href="#rid10">10-12,18</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>IgG1 comprises 60 to 70 percent of total IgG</p><p class="bulletIndent1"><span class="glyph">●</span>IgG2 comprises 20 to 30 percent</p><p class="bulletIndent1"><span class="glyph">●</span>IgG3 comprises 5 to 8 percent</p><p class="bulletIndent1"><span class="glyph">●</span>IgG4 comprises 1 to 4 percent</p><p></p><p>Because IgG1 accounts for the majority of total serum IgG, deficiencies in IgG1 often result in overall hypogammaglobulinemia. In contrast, deficiencies of the other subclasses can be accompanied by normal levels of total IgG. (See  <a class="medical medical_review" href="/d/html/3906.html" rel="external">"IgG subclass deficiency"</a>.)</p><p>Normal levels of the IgG subclasses are shown in the table  (<a class="graphic graphic_table graphicRef50967" href="/d/graphic/50967.html" rel="external">table 2</a>). The measurement of IgG subclass levels is complicated by several factors, including normal variation with age and the use of different methodologies. Although all IgG subclasses are transported through the placenta, IgG2 does not cross the placenta as readily as the other subclasses, so that newborns have lower levels of IgG2 antibodies [<a href="#rid19">19</a>]. The levels of each of the IgG subclasses rise at different rates during development. Adult IgG1 levels are present by five years of age. However, adult levels of IgG2, IgG3, and IgG4 are not achieved until adolescence  (<a class="graphic graphic_figure graphicRef58666" href="/d/graphic/58666.html" rel="external">figure 2</a>) [<a href="#rid20">20</a>].</p><p class="headingAnchor" id="H3397212"><span class="h2">Half-lives</span><span class="headingEndMark"> — </span>The half-life of IgG3 is just 7 to 8 days, due to its relative susceptibility to proteolytic enzymes, whereas the half-lives of IgG1, IgG2, and IgG4 are approximately 21 to 24 days [<a href="#rid21">21</a>].</p><p class="headingAnchor" id="H3"><span class="h1">GENETICS</span><span class="headingEndMark"> — </span>The heavy chain constant (CH) regions of an immunoglobulin molecule determine its class and subclass. The amino acid sequences of the various IgG subclasses are 90 to 95 percent homologous [<a href="#rid22">22</a>]. The CH regions are encoded by C gene segments clustered on chromosome 14 [<a href="#rid23">23</a>]. (See  <a class="medical medical_review" href="/d/html/3977.html" rel="external">"Immunoglobulin genetics"</a>.)</p><p>Each of the four subclasses has a corresponding C gene segment that encodes its CH regions  (<a class="graphic graphic_table graphicRef110543" href="/d/graphic/110543.html" rel="external">table 1</a>). As an example, the gene segment C-gamma-2 encodes the CH regions of IgG2 molecules, and C-gamma-3 encodes the corresponding regions of IgG3 molecules.</p><p class="headingAnchor" id="H3396833"><span class="h2">Allotypes</span><span class="headingEndMark"> — </span>Mutations in the C genes provide additional amino acid variation in the sequence composition of IgG subclass proteins. These mutations are inherited in an autosomal pattern and can serve as genetic markers or allotypes [<a href="#rid24">24</a>]. Thus, allotyping is used to distinguish an antibody of a particular subclass encoded by allele "a" from an antibody of the same isotype encoded by allele "b." Allotype nomenclature designates these antigenic markers by class, subclass, the letter "m," and then the allele in parentheses. As an example, G2m(n) is the n allele of IgG2 molecule. </p><p>There is evidence that IgG subclass levels are influenced by allotypes and allotype combinations under normal conditions [<a href="#rid25">25</a>]. As an example, individuals of IgG allotype G3m(5) have twice the IgG3 levels as those with IgGm(21) [<a href="#rid26">26</a>].</p><p>Allotypes can vary markedly among healthy human populations from different geographical regions [<a href="#rid27">27</a>]. It has been hypothesized that antibodies of certain allotypes may confer superior protection to pathogens indigenous to specific regions [<a href="#rid26">26</a>].</p><p class="headingAnchor" id="H4"><span class="h1">BIOLOGIC FUNCTIONS</span><span class="headingEndMark"> — </span>The biologic functions of the IgG subclasses include neutralization, opsonization, complement activation, and antibody-dependent cellular cytotoxicity.</p><p class="headingAnchor" id="H2829473188"><span class="h2">Neutralization</span><span class="headingEndMark"> — </span>Neutralization refers to the property of some IgG molecules to block the binding of viruses to host cells and to toxins to their target molecules. An example of viral neutralization is the development of IgG antibody to poliovirus following vaccination to prevent infection. An example of neutralization to toxin is the development of IgG blocking antibody to tetanus toxin following immunization with tetanus toxin to prevent "lockjaw." IgG1 and IgG3 are the predominant subclasses mediating neutralization.</p><p class="headingAnchor" id="H2280352"><span class="h2">Opsonization</span><span class="headingEndMark"> — </span>IgG1, IgG2, and IgG3 are important for opsonization of microbes by phagocytes. Opsonization refers to the binding of antibodies to the surfaces of a microbe or foreign particle in order to facilitate phagocytosis by neutrophils or macrophages via Fc-gamma-receptors. Both antibodies and complement proteins can act as opsonins. Immunoglobulin molecules interact with microbes through their Fab portions and bind to phagocytes through the Fc portion.</p><p>In contrast to the other subclasses, IgG4 has low affinity for Fc-gamma-receptors and C1q and thus minimal ability to activate cells or initiate complement activation. In addition, IgG4 antibodies may undergo Fab arm exchange resulting in two different antigen-specific antibodies. This results in loss of IgG4 antibodies to cross-link antigens and form immune complexes [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H2280359"><span class="h2">Complement activation</span><span class="headingEndMark"> — </span>The different IgG subclasses differ in their ability to bind C1q and activate the classical complement pathway  (<a class="graphic graphic_table graphicRef110543" href="/d/graphic/110543.html" rel="external">table 1</a>). IgG1 and IgG3 fix C1q most effectively, while IgG2 does so weakly. IgG4 does not bind complement at all [<a href="#rid5">5</a>]. (See  <a class="medical medical_review" href="/d/html/3968.html" rel="external">"Complement pathways", section on 'Classical pathway'</a>.)</p><p class="headingAnchor" id="H2642377228"><span class="h2">Antibody-dependent cellular cytotoxicity</span><span class="headingEndMark"> — </span>Antibody-dependent cellular cytotoxicity (ADCC) is a mechanism in which Fc-gamma-receptor-bearing effector cells, such a NK cells, bind IgG antibody recognizing antigens on target cells. IgG1 is the predominant IgG subclass displaying ADCC activity. ADCC is discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/3949.html" rel="external">"NK cell deficiency syndromes: Clinical manifestations and diagnosis", section on 'Antibody-dependent cellular cytotoxicity'</a>.)</p><p class="headingAnchor" id="H5"><span class="h2">Role in specific types of infections</span><span class="headingEndMark"> — </span>Antibody responses to certain types of pathogens are predominantly comprised of molecules of a specific IgG subclass, which is referred to as IgG subclass restriction  (<a class="graphic graphic_table graphicRef110543" href="/d/graphic/110543.html" rel="external">table 1</a>). Specifically:</p><p class="bulletIndent1"><span class="glyph">●</span>Antibody responses to bacterial polysaccharide antigens, such as the capsular antigens of <em>Streptococcus pneumoniae</em>, are composed mainly of IgG2 molecules [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antibody responses to protein antigens and viral antigens are composed predominantly of IgG1 and IgG3 [<a href="#rid29">29,30</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The biologic role of IgG4 is incompletely understood, although the finding that antibody responses to chronic schistosomiasis and filariases are primarily composed of IgG4 molecules suggests that IgG4 may play a role in the immune response against parasitic disease [<a href="#rid31">31,32</a>]. Total and antigen-specific IgG3 and IgG4 were elevated in Indian children with visceral leishmaniasis [<a href="#rid33">33</a>].</p><p></p><p class="headingAnchor" id="H3397374"><span class="h1">DISORDERS WITH ELEVATED SUBCLASS LEVELS</span><span class="headingEndMark"> — </span>Increased serum IgG4 levels have been reported in several disorders:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>IgG gammopathies</strong> – Markedly elevated levels of any of the IgG subclasses, often with diminution of the others, is characteristic of the IgG gammopathies, including multiple myeloma or benign monoclonal IgG paraproteins. These patients should be referred to a hematologist. (See  <a class="medical medical_review" href="/d/html/6652.html" rel="external">"Diagnosis of monoclonal gammopathy of undetermined significance"</a> and  <a class="medical medical_review" href="/d/html/6649.html" rel="external">"Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>IgG4-related disease (IgG4-RD)</strong> – IgG4-RD is a rare systemic immune-mediated disorder first described in older Japanese men in the early 2000s but now recognized in other patient populations and in diverse areas of the world. It is characterized by tumor-like swelling of involved organs, elevated serum levels of IgG4 (ie, ≥135 mg/dL), lymphoplasmacytic infiltrates enriched in IgG4-positive plasma cells and variable degrees of fibrosis, and responsiveness to glucocorticoids, particularly in the early stages of disease. IgG4-RD is reviewed in detail separately. These patients should be referred to a rheumatologist.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Allergic disorders</strong> – Patients with allergic disorders, such as atopic dermatitis, may demonstrate elevated levels of IgG4, probably due to prolonged allergen stimulation [<a href="#rid34">34</a>]. In addition, patients receiving allergen immunotherapy develop increased levels of allergen-specific IgG4, although this usually does not impact the total serum IgG4. These patients should be referred to an allergist. (See  <a class="medical medical_review" href="/d/html/362.html" rel="external">"Allergen immunotherapy for allergic disease: Therapeutic mechanisms", section on '"Blocking" IgG4'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Idiopathic membranous nephropathy</strong> – Increased levels of IgG4 have been described in idiopathic membranous nephropathy, in association with increased interleukin 10 (IL-10) and interleukin 13 (IL-13) mRNA expression [<a href="#rid35">35</a>]. These patients should be referred to a nephrologist. (See  <a class="medical medical_review" href="/d/html/3050.html" rel="external">"Membranous nephropathy: Pathogenesis and etiology", section on 'Pathogenesis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulmonary disorders</strong> – A variety of pulmonary disorders, including Loeffler syndrome, leiomyosarcoma, periarteritis nodosa, and mycosis fungoides, have been associated with elevated IgG4 levels [<a href="#rid36">36-38</a>]. These patients should be referred to a pulmonologist.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rheumatoid arthritis</strong> – Elevated IgG4 levels have also been reported in rheumatoid arthritis [<a href="#rid39">39</a>]. These patients should be referred to a rheumatologist. (See  <a class="medical medical_review" href="/d/html/7504.html" rel="external">"Diagnosis and differential diagnosis of rheumatoid arthritis", section on 'Evaluation and diagnosis'</a>.)</p><p></p><p class="headingAnchor" id="H3397367"><span class="h1">DISORDERS WITH REDUCED SUBCLASS LEVELS</span><span class="headingEndMark"> — </span>Decreased levels of IgG subclasses are seen in the normal population but can also be associated with increased frequency and severity of infections, particularly of the upper and lower respiratory tract. IgG subclass deficiency is considered to be a primary immunodeficiency when reduced levels of one or more IgG subclasses (with normal total IgG) are accompanied by impaired antibody function (usually demonstrated by abnormal vaccine response). This disorder is reviewed separately. These patients should be referred to an immunologist. (See  <a class="medical medical_review" href="/d/html/3906.html" rel="external">"IgG subclass deficiency"</a>.)</p><p class="headingAnchor" id="H22335714"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>Immunoglobulin G (IgG) is comprised of four subclasses: IgG1, IgG2, IgG3, and IgG4. All four subclasses are monomeric and have similar structures. All cross the placenta. (See <a class="local">'Properties of IgG subclasses'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>IgG subclasses are numbered according to their serum concentrations. IgG1 normally comprises 60 to 70 percent of total IgG, such that low levels of IgG1 usually results in overall hypogammaglobulinemia. (See <a class="local">'Normal serum concentrations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The class and subclass of an immunoglobulin molecule are determined by the constant heavy chain (CH) portion. The amino acid sequences of the various IgG subtypes are 90 to 95 percent homologous, with each subtype having a specific CH gene segment that encodes its CH region (eg, gene segment C-gamma-2 encodes the CH regions of IgG2 molecules). (See <a class="local">'Genetics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>All four IgG subclasses act as opsonins, binding to microbes and facilitating phagocytosis. They have differing abilities to activate the classical complement pathway: IgG1 and IgG3 fix C1q most effectively activating the classical complement pathway, while IgG2 does so weakly, and IgG4 does not bind complement at all  (<a class="graphic graphic_table graphicRef110543" href="/d/graphic/110543.html" rel="external">table 1</a>). (See <a class="local">'Biologic functions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Many IgG antibody responses to pathogens demonstrate "IgG subclass restriction," which means the response is largely composed of certain IgG subtypes. Antibody responses to protein antigens and viral antigens are composed predominantly of IgG1 and IgG3, while responses to polysaccharide antigens are mostly IgG2. (See <a class="local">'Role in specific types of infections'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The functions of IgG4 remain incompletely defined. It may play a role in the immune response to parasitic infection, but elevations in IgG4 have also been associated with an array of different disorders. (See <a class="local">'Disorders with elevated subclass levels'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Low levels of one or more of the IgG subclasses are found in healthy people but can also be associated with increased infections and poor vaccine response. The latter is considered to be a form of primary immunodeficiency. (See  <a class="medical medical_review" href="/d/html/3906.html" rel="external">"IgG subclass deficiency"</a>.)</p><p></p><p class="headingAnchor" id="H1487971765"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges J Keith Lemmon, MD, and E Richard Stiehm, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Pan Q, Hammarström L. Molecular basis of IgG subclass deficiency. Immunol Rev 2000; 178:99.</a></li><li class="breakAll">Meulenbroek AJ, Zeijlemaker WP. Human IgG subclasses: Useful diagnostic markers for immunocompetence, 2nd edition, CLB, Amsterdam, The Netherlands 2000.</li><li><a class="nounderline abstract_t">GREY HM, KUNKEL HG. H CHAIN SUBGROUPS OF MYELOMA PROTEINS AND NORMAL 7S GAMMA-GLOBULIN. J Exp Med 1964; 120:253.</a></li><li><a class="nounderline abstract_t">TERRY WD, FAHEY JL. SUBCLASSES OF HUMAN GAMMA-2-GLOBULIN BASED ON DIFFERENCES IN THE HEAVY POLYPEPTIDE CHAINS. Science 1964; 146:400.</a></li><li><a class="nounderline abstract_t">Burton DR, Gregory L, Jefferis R. Aspects of the molecular structure of IgG subclasses. Monogr Allergy 1986; 19:7.</a></li><li><a class="nounderline abstract_t">Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol 2014; 5:520.</a></li><li><a class="nounderline abstract_t">Schroeder HW Jr, Cavacini L. Structure and function of immunoglobulins. J Allergy Clin Immunol 2010; 125:S41.</a></li><li class="breakAll">Carsetti R, Plebani A, Ugazio AG, et al. B lymphocytes and immunoglobulins. In: Immunology IV: Clinical Application in Health and Disease, Bellanti JA (Ed), Care Press, Bethesda, MD 2012. p.163.</li><li class="breakAll">van der Berg M, Weemaes CMR, Cunningham-Rundles C. Isotype defects. In: Immune Deficiencies, Sullivan KE, Stiehm ER (Eds), Academic Press Elsevier, Amsterdam 2014. p.389.</li><li><a class="nounderline abstract_t">Brito-Zerón P, Ramos-Casals M, Bosch X, Stone JH. The clinical spectrum of IgG4-related disease. Autoimmun Rev 2014; 13:1203.</a></li><li><a class="nounderline abstract_t">Stone JH, Brito-Zerón P, Bosch X, Ramos-Casals M. Diagnostic Approach to the Complexity of IgG4-Related Disease. Mayo Clin Proc 2015; 90:927.</a></li><li><a class="nounderline abstract_t">Neild GH, Rodriguez-Justo M, Wall C, Connolly JO. Hyper-IgG4 disease: report and characterisation of a new disease. BMC Med 2006; 4:23.</a></li><li><a class="nounderline abstract_t">Jefferis R, Pound J, Lund J, Goodall M. Effector mechanisms activated by human IgG subclass antibodies: clinical and molecular aspects. Review article. Ann Biol Clin (Paris) 1994; 52:57.</a></li><li><a class="nounderline abstract_t">van der Neut Kolfschoten M, Schuurman J, Losen M, et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 2007; 317:1554.</a></li><li><a class="nounderline abstract_t">Schuurman J, Van Ree R, Perdok GJ, et al. Normal human immunoglobulin G4 is bispecific: it has two different antigen-combining sites. Immunology 1999; 97:693.</a></li><li><a class="nounderline abstract_t">Pumphrey R. Computer models of the human immunoglobulins shape and segmental flexibility. Immunol Today 1986; 7:174.</a></li><li><a class="nounderline abstract_t">Sigal LH. Basic science for the clinician 58: IgG subclasses. J Clin Rheumatol 2012; 18:316.</a></li><li><a class="nounderline abstract_t">French M. Serum IgG subclasses in normal adults. Monogr Allergy 1986; 19:100.</a></li><li><a class="nounderline abstract_t">Garty BZ, Ludomirsky A, Danon YL, et al. Placental transfer of immunoglobulin G subclasses. Clin Diagn Lab Immunol 1994; 1:667.</a></li><li><a class="nounderline abstract_t">Lee SI, Heiner DC, Wara D. Development of serum IgG subclass levels in children. Monogr Allergy 1986; 19:108.</a></li><li><a class="nounderline abstract_t">Morell A, Terry WD, Waldmann TA. Metabolic properties of IgG subclasses in man. J Clin Invest 1970; 49:673.</a></li><li><a class="nounderline abstract_t">Jefferis R, Reimer CB, Skvaril F, et al. Evaluation of monoclonal antibodies having specificity for human IgG sub-classes: results of an IUIS/WHO collaborative study. Immunol Lett 1985; 10:223.</a></li><li><a class="nounderline abstract_t">Hofker MH, Walter MA, Cox DW. Complete physical map of the human immunoglobulin heavy chain constant region gene complex. Proc Natl Acad Sci U S A 1989; 86:5567.</a></li><li><a class="nounderline abstract_t">Lefranc MP, Hammarström L, Smith CI, Lefranc G. Gene deletions in the human immunoglobulin heavy chain constant region locus: molecular and immunological analysis. Immunodefic Rev 1991; 2:265.</a></li><li><a class="nounderline abstract_t">Sarvas H, Rautonen N, Mäkelä O. Allotype-associated differences in concentrations of human IgG subclasses. J Clin Immunol 1991; 11:39.</a></li><li class="breakAll">Ochs HD. The B-lymphocyte system: Clinical immunology. In: Immunologic disorders in infants and children, 5th ed, Stiehm ER, Ochs HD, Winkelstein JA (Eds), Elsevier, Philadelphia 2004. p.89.</li><li><a class="nounderline abstract_t">Steinberg AG. Globulin polymorphisms in man. Annu Rev Genet 1969; 3:25.</a></li><li><a class="nounderline abstract_t">Siber GR, Schur PH, Aisenberg AC, et al. Correlation between serum IgG-2 concentrations and the antibody response to bacterial polysaccharide antigens. N Engl J Med 1980; 303:178.</a></li><li><a class="nounderline abstract_t">Stevens R, Dichek D, Keld B, Heiner D. IgG1 is the predominant subclass of in vivo- and in vitro- produced anti-tetanus toxoid antibodies and also serves as the membrane IgG molecule for delivering inhibitory signals to anti-tetanus toxoid antibody-producing B cells. J Clin Immunol 1983; 3:65.</a></li><li><a class="nounderline abstract_t">Spinsanti LI, Farías AA, Aguilar JJ, et al. Immunoglobulin G subclasses in antibody responses to St. Louis encephalitis virus infections. Arch Virol 2011; 156:1861.</a></li><li><a class="nounderline abstract_t">Iskander R, Das PK, Aalberse RC. IgG4 antibodies in Egyptian patients with schistosomiasis. Int Arch Allergy Appl Immunol 1981; 66:200.</a></li><li><a class="nounderline abstract_t">Ottesen EA, Skvaril F, Tripathy SP, et al. Prominence of IgG4 in the IgG antibody response to human filariasis. J Immunol 1985; 134:2707.</a></li><li><a class="nounderline abstract_t">Ansari NA, Kumar R, Raj A, Salotra P. Elevated levels of IgG3 and IgG4 subclass in paediatric cases of kala azar. Parasite Immunol 2008; 30:403.</a></li><li><a class="nounderline abstract_t">Aalberse RC, Van Milligen F, Tan KY, Stapel SO. Allergen-specific IgG4 in atopic disease. Allergy 1993; 48:559.</a></li><li><a class="nounderline abstract_t">Kuroki A, Iyoda M, Shibata T, Sugisaki T. Th2 cytokines increase and stimulate B cells to produce IgG4 in idiopathic membranous nephropathy. Kidney Int 2005; 68:302.</a></li><li><a class="nounderline abstract_t">van Nieuwkoop JA, Brand A, Radl J, Skvaril F. Increased levels of IgG4 subclass in 5 patients with acquired respiratory disease. Int Arch Allergy Appl Immunol 1982; 67:61.</a></li><li><a class="nounderline abstract_t">Yamamoto M, Takahashi H, Suzuki C, et al. Analysis of serum IgG subclasses in Churg-Strauss syndrome--the meaning of elevated serum levels of IgG4. Intern Med 2010; 49:1365.</a></li><li><a class="nounderline abstract_t">Tsushima K, Yokoyama T, Kawa S, et al. Elevated IgG4 levels in patients demonstrating sarcoidosis-like radiologic findings. Medicine (Baltimore) 2011; 90:194.</a></li><li><a class="nounderline abstract_t">Engelmann R, Brandt J, Eggert M, et al. IgG1 and IgG4 are the predominant subclasses among auto-antibodies against two citrullinated antigens in RA. Rheumatology (Oxford) 2008; 47:1489.</a></li></ol></div><div id="topicVersionRevision">Topic 3964 Version 18.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11213812" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Molecular basis of IgG subclass deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11213812" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Molecular basis of IgG subclass deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14206440" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : H CHAIN SUBGROUPS OF MYELOMA PROTEINS AND NORMAL 7S GAMMA-GLOBULIN.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14186462" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : SUBCLASSES OF HUMAN GAMMA-2-GLOBULIN BASED ON DIFFERENCES IN THE HEAVY POLYPEPTIDE CHAINS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2945094" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Aspects of the molecular structure of IgG subclasses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25368619" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : IgG subclasses and allotypes: from structure to effector functions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20176268" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Structure and function of immunoglobulins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20176268" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Structure and function of immunoglobulins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20176268" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Structure and function of immunoglobulins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25151972" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The clinical spectrum of IgG4-related disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26141331" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Diagnostic Approach to the Complexity of IgG4-Related Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17026742" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Hyper-IgG4 disease: report and characterisation of a new disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8210076" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Effector mechanisms activated by human IgG subclass antibodies: clinical and molecular aspects. Review article.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17872445" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10457225" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Normal human immunoglobulin G4 is bispecific: it has two different antigen-combining sites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25290203" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Computer models of the human immunoglobulins shape and segmental flexibility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22955484" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Basic science for the clinician 58: IgG subclasses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3762537" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Serum IgG subclasses in normal adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8556518" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Placental transfer of immunoglobulin G subclasses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3762538" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Development of serum IgG subclass levels in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5443170" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Metabolic properties of IgG subclasses in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3899923" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Evaluation of monoclonal antibodies having specificity for human IgG sub-classes: results of an IUIS/WHO collaborative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2501792" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Complete physical map of the human immunoglobulin heavy chain constant region gene complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1905558" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Gene deletions in the human immunoglobulin heavy chain constant region locus: molecular and immunological analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2022720" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Allotype-associated differences in concentrations of human IgG subclasses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2022720" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Allotype-associated differences in concentrations of human IgG subclasses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Globulin polymorphisms in man</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6966763" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Correlation between serum IgG-2 concentrations and the antibody response to bacterial polysaccharide antigens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6600745" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : IgG1 is the predominant subclass of in vivo- and in vitro- produced anti-tetanus toxoid antibodies and also serves as the membrane IgG molecule for delivering inhibitory signals to anti-tetanus toxoid antibody-producing B cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21688106" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Immunoglobulin G subclasses in antibody responses to St. Louis encephalitis virus infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7287200" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : IgG4 antibodies in Egyptian patients with schistosomiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2579154" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Prominence of IgG4 in the IgG antibody response to human filariasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18466200" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Elevated levels of IgG3 and IgG4 subclass in paediatric cases of kala azar.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8116855" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Allergen-specific IgG4 in atopic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15954921" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Th2 cytokines increase and stimulate B cells to produce IgG4 in idiopathic membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7056589" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Increased levels of IgG4 subclass in 5 patients with acquired respiratory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20647649" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Analysis of serum IgG subclasses in Churg-Strauss syndrome--the meaning of elevated serum levels of IgG4.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21512409" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Elevated IgG4 levels in patients demonstrating sarcoidosis-like radiologic findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18703528" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : IgG1 and IgG4 are the predominant subclasses among auto-antibodies against two citrullinated antigens in RA.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
